A retrospective analysis of combined chemoradiotherapy for locally advanced esophageal carcinoma
10.3781/j.issn.1000-7431.2008.11.015
- Author:
Mei GENG
1
Author Information
1. Department of Oncology
- Publication Type:Journal Article
- Keywords:
Chemotherapy, adjuvant;
Esophageal neoplasms;
Prognosis;
Radiotherapy
- From:
Tumor
2008;28(11):972-975
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the clinical response and prognosis of patients with locally advanced esophageal carcinoma after being treated with combined chemoradiotherapy. Methods: Thirty-five patients with locally advanced esophageal carcinoma were treated with radiotherapy (total radiation dosage, 45.0-50.4 Gy) and chemotherapy (5-FU plus cisplatin). Clinical response and survival time were analyzed according to their clinicopathological features. Results: The response rate was significantly higher in the patients who had the opportunity of surgery after chemoradiotherapy than those without opportunity of surgery (83.33% vs 47.83%, P = 0.023). Survival analysis confirmed that short-term efficacy and clinical staging were the important factors for progression-free survival (PFS) of patients (P <0.01, P <0.05). The efficacy of chemoradiotherapy affected overall survival (OS) statistically. The median OS for the patients with complete and partial response, stable disease, and progressed disease were 18 months, 15 months, and 6 months, respectively (P = 0.003). Conclusion: Combined chemoradiotherapy is effective in the treatment of locally advanced esophageal carcinoma. The efficacy of chemoradiotherapy is an important prognostic factor for progression-free survival and overall survival of patients.
